May 19 -- MONDAY, May 18 (HealthDay News) -- The Janssen Pharmaceuticals drug Risperdal Consta (risperidone) has been approved by the U.S. Food and Drug Administration for people with Bipolar 1 ...
NY Attorney General Eric Schneiderman announced a record $181 million settlement with Janssen Pharmaceuticals and its parent company Johnson & Johnson to resolve charges of improper marketing and ...
Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...
J&J to Pay $2.2B Settlement to End Risperdal Probes New Brunswick, N.J.-based Johnson & Johnson has agreed to pay up to $2.2 billion to settle U.S. investigations and lawsuits regarding its marketing ...
Hosted on MSN
Lupin Gains After USFDA Nod for Risperidone Injectable To Treat Schizophrenia And Bipolar I Disorder
Lupin’s shares rose 2.8% in afternoon trading after the company received a key U.S. Food and Drug Administration (FDA) approval. On Wednesday, Lupin received USFDA approval for its Abbreviated New ...
A Philadelphia jury ordered Johnson & Johnson to pay $8 billion in punitive damages in a case accusing the drugmaker of downplaying the risks associated with its antipsychotic drug, Risperdal, ...
Risperdal, which has already been cleared by the FDA as a treatment for bipolar disorder, is one of J&J’s biggest products, with annual sales of about $3 billion.New Brunswick”s Johnson & Johnson ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback